Align Technology, Inc. $ALGN Shares Sold by Carmignac Gestion

Carmignac Gestion trimmed its holdings in Align Technology, Inc. (NASDAQ:ALGN) by 8.5% in the first quarter, Holdings Channel.com reports. The institutional investor owned 225,171 shares of the medical equipment provider’s stock after selling 20,930 shares during the quarter. Carmignac Gestion’s holdings in Align Technology were worth $38,537,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Capital International Investors grew its holdings in shares of Align Technology by 52.2% during the fourth quarter. Capital International Investors now owns 4,643,221 shares of the medical equipment provider’s stock worth $725,039,000 after buying an additional 1,592,848 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. purchased a new stake in Align Technology during the 4th quarter valued at approximately $190,899,000. Norges Bank purchased a new stake in Align Technology during the 4th quarter valued at approximately $155,556,000. Assenagon Asset Management S.A. lifted its position in Align Technology by 413.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 989,388 shares of the medical equipment provider’s stock worth $169,611,000 after acquiring an additional 796,529 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in Align Technology by 247.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,005,413 shares of the medical equipment provider’s stock worth $156,995,000 after acquiring an additional 715,919 shares during the period. Institutional investors and hedge funds own 88.43% of the company’s stock.

Key Stories Impacting Align Technology

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Q2 results exceeded expectations. Align reported adjusted earnings of $2.64 per share and revenue of approximately $1.06 billion, topping consensus estimates. Revenue increased 4.3% year over year, while record Clear Aligner shipments and improved non-GAAP margins supported profitability. Align Technology Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Digital orthodontics remains a growth focus. Management highlighted expanding digital workflows, connected orthodontic tools and long-term opportunities for Invisalign, iTero scanners and exocad software. The company’s 2026 outlook was reaffirmed, while an orthodontic summit showcased its product and technology strategy. ALGN Q2 Earnings Call Highlights Digital Growth Push
• Positive Sentiment: Board changes could improve shareholder value. Following discussions with Elliott Investment Management, Align plans to add three independent directors and conduct an operational review. The initiatives may increase accountability, improve execution and identify opportunities to enhance returns. Align Technology to Overhaul Board Following Engagement with Elliott
• Neutral Sentiment: Valuation is viewed as more attractive after the pullback. Some analysts see ALGN as reasonably valued, but believe the stock needs faster growth to generate sustained upside. Align Technology: Attractively Valued, But Growth Still Needs To Pick Up
• Negative Sentiment: Near-term guidance and execution remain concerns. Third-quarter revenue guidance of roughly $1.0 billion was described as slightly below or around expectations, limiting the benefit of the earnings beat.
• Negative Sentiment: Systems weakness is capping upside. Analysts noted softer scanner and systems performance, along with pricing pressure, despite strong Clear Aligner volumes. Needham maintained a Hold rating. Align Technology Hold Rating Maintained
• Negative Sentiment: Growth is still relatively modest. Investors may remain cautious because revenue growth has not yet accelerated enough to justify a more bullish outlook, even with improving margins and record aligner shipments.

Analyst Ratings Changes

Several research analysts have weighed in on ALGN shares. Citigroup assumed coverage on Align Technology in a research note on Wednesday, April 15th. They issued a “buy” rating and a $240.00 target price on the stock. BMO Capital Markets initiated coverage on Align Technology in a report on Wednesday, July 8th. They set an “outperform” rating and a $209.00 price target for the company. UBS Group reiterated a “neutral” rating and issued a $189.00 price objective on shares of Align Technology in a research report on Thursday, July 23rd. Leerink Partners lifted their price objective on shares of Align Technology from $225.00 to $230.00 in a research report on Thursday, April 30th. Finally, Zacks Research cut shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $206.36.

Align Technology Stock Performance

Shares of ALGN opened at $169.16 on Monday. Align Technology, Inc. has a twelve month low of $122.00 and a twelve month high of $200.43. The stock’s 50 day moving average is $174.55 and its two-hundred day moving average is $175.23. The firm has a market capitalization of $12.12 billion, a PE ratio of 29.42, a P/E/G ratio of 1.78 and a beta of 1.65.

Align Technology (NASDAQ:ALGN) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.02. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Align Technology had a return on equity of 15.86% and a net margin of 9.99%.The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.49 EPS. On average, sell-side analysts predict that Align Technology, Inc. will post 9.48 EPS for the current year.

Align Technology declared that its board has initiated a stock buyback program on Wednesday, April 29th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the medical equipment provider to buy up to 1.6% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Align Technology Profile

Align Technology, Inc (NASDAQ: ALGN) pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company’s signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.